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Enhanced expression of JAK-STAT Pathway Members in
Human Diabetic Nephropathy
Abstract
Objective. Glomerular mesangial expansion and podocyte loss are important early features of diabetic
nephropathy (DN) whereas tubulointerstitial injury and fibrosis are critical for progression of DN to
kidney failure. Therefore, we analyzed the expression of genes in glomeruli and tubulointerstitium in
kidney biopsies from DN patients to identify pathways that may be activated in humans but are not in
murine models of DN that fail to progress to glomerulosclerosis, tubulointerstitial fibrosis and kidney
failure. Research Design and Methods. Kidney biopsies were obtained from 74 patients (controls, early
and progressive type 2 DN). Glomerular and tubulointerstitial mRNAs were microarrayed, followed by
bioinformatics analyses. Gene expression changes were confirmed by real-time RT-PCR and
immunohistological staining. Samples from db/db C57BLKS and streptozotocin-DBA/2J mice,
commonly studied murine models of DN, were analyzed. Results. In human glomeruli and
tubulointerstitial samples, the Jak/Stat pathway was highly and significantly regulated. Jak-1, 2 and 3 as
well as Stat-1 and Stat-3 were expressed at higher levels in patients with DN than in controls. The
estimated glomerular filtration rate significantly correlated with tubulointerstitial Jak1, 2, 3 and Stat1
expression (R(2)=0.30-0.44). Immunohistochemistry found strong Jak2 staining in glomerular and
tubulointerstitial compartments in DN compared to controls. In contrast, there was little or no increase
in expression of Jak/Stat genes in the db/db C57BLKS or diabetic DBA/2J mice. Conclusions. These
data suggest a direct relationship between tubulointerstitial Jak/Stat expression and progression of
kidney failure in patients with type 2 DN and distinguishes progressive human DN from
non-progressive murine DN.
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ABSTRACT 
 
Objective. Glomerular mesangial expansion and podocyte loss are important early 
features of diabetic nephropathy (DN) whereas tubulointerstitial injury and fibrosis are 
critical for progression of DN to kidney failure.  Therefore, we analyzed the expression of 
genes in glomeruli and tubulointerstitium in kidney biopsies from DN patients to identify 
pathways that may be activated in humans but are not in murine models of DN that fail to 
progress to glomerulosclerosis, tubulointerstitial fibrosis and kidney failure. 
 
Research Design and Methods.  Kidney biopsies were obtained from 74 patients 
(controls, early and progressive type 2 DN).  Glomerular and tubulointerstitial mRNAs 
were microarrayed, followed by bioinformatics analyses.  Gene expression changes were 
confirmed by real-time RT-PCR and immunohistological staining.  Samples from db/db 
C57BLKS and streptozotocin-DBA/2J mice, commonly studied murine models of DN, 
were analyzed. 
 
Results.  In human glomeruli and tubulointerstitial samples, the Jak/Stat pathway was 
highly and significantly regulated.  Jak-1, 2 and 3 as well as Stat-1 and Stat-3 were 
expressed at higher levels in patients with DN than in controls.  The estimated glomerular 
filtration rate significantly correlated with tubulointerstitial Jak1, 2, 3 and Stat1 expression 
(R2=0.30-0.44).  Immunohistochemistry found strong Jak2 staining in glomerular and 
tubulointerstitial compartments in DN compared to controls.  In contrast, there was little or 
no increase in expression of Jak/Stat genes in the db/db C57BLKS or diabetic DBA/2J 
mice.  
 
Conclusions. These data suggest a direct relationship between tubulointerstitial Jak/Stat 
expression and progression of kidney failure in patients with type 2 DN and distinguishes 
progressive human DN from non-progressive murine DN. 
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arly clinical diabetic nephropathy 
(DN) is characterized by 
progressive increases in 
albuminuria which are associated with the 
development of characteristic 
histopathologic features including 
thickening of the glomerular basement 
membrane and mesangial expansion due 
to accumulation of extracellular matrix 
proteins (1).  As albuminuria progresses 
and renal insufficiency ensues, 
glomerulosclerosis, arteriolar hyalinosis, 
and tubulointerstitial fibrosis develop (2).  
Mesangial expansion and the degree of 
tubulointerstitial fibrosis correlate 
inversely with glomerular filtration rate in 
humans with diabetic kidney disease and 
appear to be critical steps in the 
progression of DN to end stage renal 
disease (ESRD) (1; 3; 4). Over 20 years 
ago, Mauer and colleagues established 
the clear link between mesangial matrix 
expansion and progression of diabetic 
kidney disease by demonstrating that 
measures of mesangial expansion 
strongly predicted the clinical 
manifestations of DN [1].  The critical role 
of tubulointerstitial expansion and fibrosis 
in the progression of DN has also been 
recognized for at least 2 decades [1, 5].  
Tubulointerstitial changes, including 
fibrosis, appear to be critical for final 
progression of DN to kidney failure in 
Type 1 patients, and may play an even 
more important, though heterogeneous, 
role in Type 2 patients [6]. Despite 
agreement about these pathologic 
predictors, there is no consensus about 
the processes that lead to progressive 
glomerulosclerosis and tubulointerstitial 
fibrosis. 
While hypothesis driven studies have 
led to many insights about the 
development and progression of DN, 
there is recent interest in using more 
broad-based approaches to 
understanding the pathogenesis of 
human renal disease (7-9).  Moreover, 
while current animal models of DN 
replicate well the early stages of human 
disease, virtually all fail to develop the 
severe glomerulosclerosis, progressive 
tubulointerstitial fibrosis and gradual 
decline in glomerular filtration rate that 
characterize human DN (10).  Therefore, 
use of a broad-based approach with 
tissues from human patients with 
progressive DN might allow elucidation of 
pathways that would not be observed in 
hypothesis based studies of animal or cell 
models (7-9).  In this report, we show that 
a transcriptomic analysis of glomerular 
and tubulointerstitial tissues from patients 
with early and progressive DN reveals 
regulation of the expression of multiple 
members of the Jak/Stat pathway. 
E
We focused on these results because 
the activation of Jak/Stat signaling 
pathways can be implicated in both 
tubulointerstitial fibrosis and epithelial to 
mesenchymal transition in several 
conditions, including diabetes, in animal 
models (11-13).  Similarly, Jak/Stat 
activation is reported in rat glomerular 
cells exposed to high glucose (14;15) and 
may be important in the glomerular TGF-
β activation and fibronectin accumulation 
critical for extracellular matrix deposition 
in early DN (15).  Moreover, angiotensin 
converting enzyme inhibitors and 
angiotensin receptor blockers, which 
prevent the progression of DN, also 
prevent Jak/Stat activation in glomerular 
cells from diabetic rats (14).  Therefore, 
we studied expression and effects of 
Jak/Stat members in human and mouse 
DN. 
 
RESEARCH DESIGN AND METHODS 
Human renal biopsy samples for 
genome-wide expression profiling and 
real-time RT-PCR. Gene expression 
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profiling of 74 kidney biopsies was 
performed essentially as reported by 
Cohen CD et al. (16) and Lindenmeyer et 
al. (17). For a detailed description, see 
the Supplementary Material.  Clinical 
data for these patients are provided in the 
Supplementary Tables 1 and 2. 
Microarray target preparation, data 
processing, analysis and pathway 
mapping. Microarrays from extracted 
microdissected renal compartment RNAs 
were processed following a previously 
published protocol (18). The CEL files 
were processed by the ChipInspector 
software (Genomatix Software GmbH; 
http://www.genomatix.de).  Briefly and as 
described in the user manual, 
ChipInspector extracted the single probes 
significantly differentially expressed in 
Affymetrix GeneChip microarrays (false 
discovery rate (fdr) = 0).  In the designed 
analysis treatment/control experiment, LD 
and MCD patients were the “control” 
group and the early DN (Pima Indians) or 
progressive DN (European cohort) were 
the “experiment” group. The 
ChipInspector analysis steps were: 
normalization, log2 transformation, 
statistical analysis and mapping to 
transcripts.  The resulting lists were 
uploaded into the Ingenuity Pathway 
Analysis software (IPA, 
www.ingenuity.com).  Differential 
regulation was displayed in hierarchical 
manner with color-coded expression 
levels.  All the genes of a family were 
combined and represented by the generic 
family name. 
Histology and immunohistochemistry. 
Following the protocol previously 
described (19), immunohistochemistry 
studies were performed from an 
independent cohort of controls 
(histologically verified unaffected regions 
from tumor nephrectomies), type 2 
progressive DN cases and other kidney 
disease biopsies (Supplementary Table 
3).  Jak2 staining was performed using a 
primary monoclonal antibody at 1:100 
(AHO1352, Biosource Camarillo, CA).  A 
biotinylated goat anti-mouse antibody 
(HistoLine, Zymed, Milan, Italy) was used 
as secondary antibody (1:200).   
Morphometric analysis of the 
progressive DN patients included analysis 
of the numbers of glomeruli that had 
segmental or global glomerulosclerosis or 
were sclerotic.  The presence of 
tubulointerstitial damage was determined 
by the presence of tubular atrophy, 
presence of myofibroblasts and/or 
accumulation of extracellular matrix 
proteins (Supplementary Table 4). 
Animals. Mice were obtained from The 
Jackson Laboratory (Bar Harbor, ME).  
Db/db and db/m mice on a C57BKLS 
background (BKS.Cg-m +/+ Leprdb/J) 
become obese around 3-4 weeks and 
develop hyperglycemia between 4-8 
weeks of age.  Male 10 week-old DBA/2J 
mice were allowed to acclimate to their 
environment for at least 3 days before 
injection.  Mice were fasted for 4 hours 
and then given intraperitoneal injections 
of 40 mg/kg streptozotocin (STZ) or the 
vehicle (control mice) daily for five 
consecutive days as previously reported 
(10,20).  Mice were subcutaneously 
implanted with pellets impregnated with 
bovine insulin (LinBit tablets, LinShin 
Canada, Inc., Toronto, Ontario, Canada) 
at 10 weeks, 15 weeks and 20 weeks 
post-STZ.  The administered dose of 
insulin was approximately 0.1 U/day.  
These animals were euthanized at 24 
weeks after completion of STZ injections.  
Phenotypic evaluation of the DBA/2J 
diabetic and control mice was reported 
previously (21).  Albuminuria was 
increased 3-fold, mesangial matrix was 
increased ~65% and podocyte number 
was decreased ~30% in the diabetic 
4 
 
Jak2 Expression in Human Diabetic Nephropathy 
 
DBA/2J mice compared to controls (21).  
The db/db C57BLKS mice were not 
phenotyped in this study.  However, this 
model has been extensively phenotyped 
by others in previous studies and has 
very similar changes of early diabetic 
nephropathy (22). 
The procedures used in this study 
were in accordance with the guidelines of 
the University of Michigan Committee on 
the Use and Care of Animals and 
conformed to “The Guide for the Care 
and Use of Laboratory Animals,” 
Department of Health, Education, and 
Welfare Publication No. (NIH) 86-23.  
Veterinary care was provided by the 
University of Michigan Unit for Laboratory 
Animal Medicine.  The University of 
Michigan is accredited by the American 
Association of Laboratory Animal Care. 
 
Mouse kidney samples. Kidney cortex 
and glomeruli were harvested from 32 
week-old diabetic db/db C57BLKS mice 
and their control db/m littermates and 
from STZ-diabetic and control DBA/2J 
mice 24 weeks after STZ or vehicle 
injection.  Mice were anesthetized by IP 
pentobarbital (0.06 mg/g of body weight).  
Briefly, blood was flushed from the mice 
with 0.1M Phosphate Buffered Saline 
(PBS sterile, pH 7.4) via a catheter 
inserted into the abdominal aorta.  A 20 
ml iron oxide bolus (5 mg/ml in 0.9 % 
NaCl) followed.  The right kidney was 
then removed, minced and pushed 
through a 90 μm nylon mesh (Catalog # 
03-90/49, Sefar America, Kansas City, 
MO) into a beaker over a magnet (grade 
8), used to retain the iron-perfused 
glomeruli, then washed 2 times with 
sterile PBS (pH 7.4).  One fifth of the 
glomeruli harvested were then stored in 
RNA later (Ambion, Austin-TX) for RNA 
analysis; the remaining glomeruli were 
lysed and stored at -80°C for protein 
analysis. 
Mouse RNA and protein extraction. 
Total RNA was isolated from the 
microdissected tissues using the RNeasy 
mini kit; Qiagen GmbH, Hilden, Germany, 
following the manufacturer’s instructions.  
Harvested mouse kidney samples were 
lysed in a buffer containing 10 mM Tris-
HCl pH7.4, 150 mM NaCl, 1% Triton X-
100, 0.1% SDS, 1 mM Na3VO4, 50 mM 
NaF, 1 mM PMSF and complete protease 
inhibitor cocktail (Roche, Indianapolis, 
IN), sonicated and centrifuged 20 min at 
15,000 g and 4 °C.  The supernatant was 
obtained and stored at -80°C until 
analyzed. 
Human and mouse real-time RT-PCR. 
Reverse transcription of RNA and 
amplification was performed as described 
previously (7) using commercially 
available pre-developed TaqMan 
reagents for Jak2, Stat3 and 18S 
ribosomal RNA for result normalization 
(Assay-on-demand, Applied Biosystems, 
Darmstadt, Germany).  Quantification of 
the given templates was performed 
according to the standard curve method 
for the human samples and the delta Ct 
value for the mouse samples. Serial 
dilutions of kidney cDNA were included in 
all PCR runs and served as standard 
curve.  All measurements were performed 
in duplicate.  Controls consisting of 
double distilled H20 were negative in all 
runs. 
Mesangial cell culture and 
transfection. Murine mesangial cells 
obtained from the American Type Cell 
Collection (ATCC: MES-13, cloned from 
mice transgenic for the early region of the 
SV-40 virus) were grown in low glucose 
DMEM (Gibco, BRL) containing 5% fetal 
bovine serum (FBS), 100 units/ml 
penicillin, and 100 μg/ml streptomycin in a 
humidified air/5% CO2 atmosphere at 
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37°C.  Nucleofection of mesangial cells 
was performed according to the optimized 
protocols provided by the manufacturer 
(Amaxa, Gaithersburg, MD).  Briefly, 1.5 x 
106cells were gently resuspended in 100 
µl of Amaxa® Nucleofector Solution (Cat 
No.VCA 1003), mixed with 1.5 μg Jak2 
prk-5 or vector plasmid (23).  Following 
transfection using the L-29 program on 
the Amaxa Nucleofector, cells were 
cultured for 12 h and incubated in 5.5 mM 
D-glucose + 24.5 mM mannitol, or 30 mM 
D-glucose serum free DMEM.  Cells were 
assayed 24 h later for Western blotting or 
quantification of intracellular reactive 
oxygen species (ROS).  Transfection 
efficiency as quantified by nucleofection 
of the pMAX-GFP construct (included 
with the Amaxa® kit) was ~60% (not 
shown). 
Western blot analysis. Equal amounts 
of microdissected cortex, glomerular, or 
cultured mesangial cell protein samples 
were loaded onto 7.5% SDS-PAGE gels, 
electrophoresed, and transferred onto 
nitrocellulose membranes (Schleicher & 
Schuell, Keene, NH).  The blots were 
then incubated overnight at 4°C with a 
monoclonal mouse anti-Jak2 antibody 
(AHO1352, Biosource, Camarillo, CA; 
dilutions: 1:1000 [glomeruli], 1:2000 
[cortex]), STAT3 (Cell Signaling 
Technology, Beverly, MA;  dilutions: 
1:1000 [glomeruli], 1:2000 [cortex]), 
phospho-STAT3 (Tyr705) (Cell Signaling 
Technology, Beverly, MA; dilutions: 
1:1000 [glomeruli], 1:2000 [cortex]); or 
one hour at room temperature with an 
anti-β-tubulin antibody (Millipore, Lake 
Placid, NY; dilution: 1:6000).  
Subsequently, the blots were washed and 
incubated for 1 h at room temperature 
with an HRP-conjugated goat anti-mouse 
antibody (dilution: 1:1000 [glomeruli] - 
SuperSignal West Dura Extended 
Duration Substrate kit, Pierce, Rockford, 
IL;  or 1:10000 [cortex] - SC-2031, Santa 
Cruz Biotechnology, Inc, CA).  The 
peroxidase luminescence intensity was 
measured using NIH ImageJ Software. 
Detection of intracellular ROS. 
Intracellular ROS generation was 
monitored by confocal microscopy using 
the fluoroprobe carboxymethyl-H2-
dichlorofluorescein diacetate (CM-
H2DCFDA; Molecular Probes, Inc., 
Eugene, OR).  Transfected cells were 
grown on glass Lab-Tek Chamber Slides 
(Nunc Inc., Naperville, IL) in serum-free 
DMEM for 24 h with either 5.5 mM D-
glucose + 24.5 mM mannitol, or 30 mM D-
glucose.  They were washed with PBS 
and incubated in the dark for 30 min in 
phenol red-free DMEM containing 5 µM 
CM-H2DCFDA.  CM-H2DCFDA passively 
diffuses into cells, where its acetate 
groups are cleaved by intracellular 
esterases and its thiol-reactive 
chloromethyl group reacts with 
intracellular glutathione and other thiols.  
Subsequent oxidation yields a fluorescent 
adduct that is trapped inside the cell.  
After incubation, images were captured 
with an Olympus FluoView 500 Laser 
Scanning Confocal Microscope.  Three 
fields from each of 5 separate slide wells 
were assessed for each condition.  
Fluorescence was quantified from 50 
randomly chosen cells from each slide 
well using NIH Image J software. 
Statistics. A t-test was carried out 
between the groups of patients.  A 
Bonferroni correction was performed 
when multiple samples were being 
compared. For protein analyses, a one-
way ANOVA followed by Tukey-Kramer 
post hoc analysis was performed.  p 
values < 0.05 were considered 
statistically significant.  All data are 
presented as mean ± SD or SEM, as 
noted. 
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RESULTS 
Jak/Stat pathway in human DN. 
Pathway mapping from Affymetrix 
microarray analysis identified Jak/Stat 
signaling as one of the highly regulated 
pathways in the glomerular and 
tubulointerstitial compartments of patients 
with early and progressive DN compared 
to controls (Figure 1). In the 
tubulointerstitial compartment, several 
Jak/Stat family members were down-
regulated in early DN patients, whereas 
most were expressed at higher levels in 
progressive DN patients compared to 
controls (Figure 1, upper panel).  These 
included Jak1, Jak2, Jak3, Stat1, Stat3, 
Stat4, Stat5B.  Conversely, in the 
glomerular compartment, Jak/Stat 
pathway members were mainly increased 
in early DN compared to controls then 
down-regulated in progressive DN 
(Figure 1, lower panel). 
Real time RT-PCR analysis of RNA 
from control, early and progressive DN 
microdissected biopsies was performed 
to confirm the mRNA changes of Jak/Stat 
pathway members.  As suggested by the 
microarray data, a significant regulation of 
Jak1, Jak2, Jak3, Stat1 and Stat3 
mRNAs was demonstrated in glomeruli 
from patients with early and progressive 
DN, and in the tubulointerstitium of 
patients with progressive DN. In contrast 
to the microarray data, real time RT-PCR 
found that mRNA expression of most 
Jak/Stat family members remained 
elevated in glomeruli from progressive 
DN patients compared to control samples 
(Supplementary Table 5A).  In the 
remainder of our study, we focused on 
Jak2 since it appears to play a key role in 
proinflammatory responses in both 
glomerular and tubular cells (24).  Jak2 
mRNA levels were significantly increased 
in the glomeruli of early DN patients and 
in the tubulointerstitium of patients with 
progressive DN compared to controls 
(Figure 2A).  Jak2 mRNA levels were not 
increased in glomeruli or 
tubulointerstitium from patients with other 
progressive kidney diseases 
(Supplementary Table 5B). 
The estimated glomerular filtration 
rate (eGFR) of patients with DN (early 
and progressive) as calculated by the 
Modification of Diet in Renal Disease 
study formula (25) was strongly and 
inversely correlated with Jak2 
tubulointerstitial (Figure 2B) but not 
glomerular mRNA levels as determined 
by qRT-PCR; this is also true with 
1/serum creatinine (Supplementary 
Table 5C).   Tubulointerstitial, but not 
glomerular mRNA expression of Jak1, 
Jak3, and Stat1 were also inversely and 
significantly correlated with eGFR and 
1/serum creatinine (Supplementary 
Table 5C). Mean blood pressure also 
inversely correlated with tubulointerstitial 
Jak3 mRNA expression (Supplementary 
Table 5C).   
Jak2 immunohistochemistry showed a 
robust increase in Jak2 protein 
expression in proximal tubular epithelia 
and glomerular cells in DN compared to 
controls and other progressive kidney 
diseases (Figure 2C), indicating that 
protein expression corresponded with 
mRNA levels.  In the tubulointerstitial 
regions, contribution from cellular 
elements other than tubular cells was 
minimal (data not shown). 
Jak2 expression in db/db C57BLKS 
and STZ-DBA/2J diabetic mice. Since 
common murine DN models fail to 
develop severe glomerulosclerosis or 
tubulointerstitial fibrosis and kidney 
failure, we hypothesized that these 
models would also fail to manifest critical 
gene expression changes that occur in 
humans with progressive DN.  Db/db 
C57BLKS mice and STZ-diabetic DBA/2J 
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mice develop robust changes of early DN 
(albuminuria, mesangial expansion, 
podocyte loss) but do not develop the 
significant tubulointerstitial fibrosis and 
decline in kidney function that 
characterize progressive DN in humans 
(10) (23;24).  Therefore, we specifically 
hypothesized that Jak2 expression would 
be unchanged in the glomeruli and renal 
cortex (largely tubulointerstitial tissue) of 
these two mouse models.  Indeed, Jak2 
mRNA and protein levels were similar in 
diabetic mice and their non-diabetic 
controls (Figure 3).  Jak2 protein 
expression was also sought in glomerular 
lysates of STZ-DBA/2J mice and their 
controls only 12 weeks after STZ (or 
vehicle) injections.  There was no 
difference in Jak2 protein levels on 
immunoblots of glomerular lysates from 
these animals (n = 4 in each group, data 
not shown).   
Effects of increased Jak2 expression 
in murine mesangial cells. To 
determine whether increases in Jak2 
expression alone could induce 
downstream signaling, we analyzed the 
overexpression of Jak2 in cultured mouse 
mesangial cells for 36 h.  Jak2 
overexpression in cells incubated in 
normal (5.5 mM) glucose resulted in a 3-
fold increase in phosphorylation of Stat3 
on Tyr705, consistent with Stat3 
activation (Figure 4).  There was no 
significant change in the level of total 
Stat3 protein.  Incubation in high (30 mM) 
glucose medium alone did not 
significantly enhance Stat3 
phosphorylation compared to normal (5.5 
mM glucose), but did lead to an additive 
increase in Stat3 phosphorylation in the 
Jak2 transfected cells.  We also 
determined whether increased Jak2 
expression could enhance ROS species, 
since enhanced ROS generation appears 
to be a hallmark of progressive DN in 
humans (28).  As determined by CM-
H2DCF fluorescence, a significant 
increase in ROS was observed in Jak2 
overexpressing cells compared to control 
vector cells when both cell types were 
grown in 5.5 mM glucose (Figure 5).  A 
similar increase in ROS generation was 
demonstrated in control vector cells 
incubated in 30 mM glucose media 
compared to cells grown in 5.5 mM 
glucose medium.  There was a further, 
but non-significant, increase in ROS in 
Jak2 transfected cells incubated in high 
glucose medium compared to Jak2 
transfected cells grown in normal glucose 
medium.  
 
DISCUSSION 
DN in humans requires activation of 
multiple molecular programs to become 
manifest.  The current pathophysiological 
understanding of DN is derived largely 
from analysis of animal and cellular 
models.  Several pathways were 
identified by these approaches and were 
confirmed to play critical roles in the 
evolution of DN in humans (29; 30).  
However, despite pathogenic changes in 
a variety of different signaling pathways, 
current murine models of DN fail to 
completely replicate progressive human 
DN (glomerulosclerosis, tubulointerstitital 
fibrosis and decline in glomerular filtration 
rate) (10).  This discrepancy could be due 
to partial, incomplete or temporary 
activation of critical pathogenic responses 
and/or to distinctive protective responses 
that counteract or prevent nephropathy in 
mice that are not manifest in humans.  To 
identify those human-specific pathogenic 
or murine protective pathways, we used a 
comparative transcriptomic approach to 
DN in both species. 
In human diabetes, as assessed by 
microarray analysis, and confirmed by 
RT-PCR and immunohistochemistry, the 
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Jak/Stat signaling pathway appeared to 
be one of the top regulated pathways and 
was consistently altered in both glomeruli 
and tubulointerstitium from patients with 
DN.  Marrero’s group previously has 
identified Jak/Stat activation as potentially 
pathogenic in mediating angiotenisin II 
signaling, in inducing TGF-β expression, 
and in stimulating extracellular matrix 
protein production in cultured mesangial 
cells and animal models of DN (14; 15; 
24; 31; 32).  However, to our knowledge 
the current report is the first study to 
demonstrate enhanced Jak/Stat 
expression in human DN.  While multiple 
members of the Jak/Stat family showed 
increased mRNA expression in 
microarrays and RT-PCR expression 
studies, we focused on the expression 
patterns of Jak2, since it is a critical 
upstream regulator of many Jak/Stat 
signaling events, and was already 
implicated in processes that enhance 
fibrosis and epithelial mesenchymal 
transition in DN (11; 13-15; 24; 31; 32). 
Our findings suggest an interesting 
compartmental and temporal association 
of enhanced Jak2 expression.  
Glomerular Jak2 mRNA levels increase 
several-fold in diabetic patients with early 
DN and then decline in later stages as 
tubulointerstitial Jak2 increases along 
with progressive tubulointerstitial fibrosis 
and reduction in kidney function.  Thus, 
enhanced Jak2 expression temporally 
corresponds to the evolution of human 
DN, with glomerulopathy followed by 
tubulointerstitial fibrosis.  The impressive 
inverse correlation between 
tubulointerstitial Jak2 expression and that 
of other Jak/Stat members with eGFR 
suggests a potential causal relationship 
between enhanced Jak/Stat expression 
and progressive tubulointerstitial fibrosis 
and renal failure.  While some of this 
apparent correlation could be due to 
population differences between the early 
DN group, who are all Pima Indians, and 
the mostly European progressive DN 
group, a strong correlation between 
tubulointerstitial Jak2 expression and 
eGFR remained in the progressive DN 
group alone, suggesting that this 
association was not due to population 
differences. 
Jak2 mRNA induction in DN was 
confirmed by immunochemistry and 
appears to be DN specific, as there was 
no induction of Jak2 mRNA in glomeruli 
or tubulointerstitum in lupus nephritis, IgA 
Nephropathy, or hypertensive 
nephrosclerosis.  Jak2 protein expression 
was increased in both glomeruli and 
proximal tubular cells in humans with DN, 
but variable expression in other 
nephropathies with tubular damage and 
proteinuria, consistent with the notion that 
Jak2 activation is not generic to all 
progressive renal diseases.  This 
observation confirmed the results 
obtained by Affymetrix GeneChip 
compared to control patients (living 
donors, n=21), where Jak2  mRNA 
showed no consistent regulation in 
patients with hypertensive nephropathy 
(n=20), IgA nephropathy (n=27) and 
lupus nephritis (n=32) with fold changes 
between 0.93 and 1.10 in the glomerular 
and tubulointerstitial compartments.  
Similarly, there was no correlation 
between gene expression of Jak2 or 
other Jak/Stat members in DN samples 
with blood pressure, duration of diabetes, 
glycosylated hemoglobin or body mass 
index (with the sole exception of Jak3 and 
blood pressure), suggesting that the 
correlation with eGFR was specific and 
not due to some confounding factor.  
Nonetheless, a significant correlation 
between Jak2 and eGFR does not 
necessarily imply a causal connection 
between the two parameters, nor a 
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directionality if a causal relationship 
exists.  It will be imperative to follow up 
these studies with prospective analysis of 
patients with DN to determine whether 
either glomerular or tubulointerstitial Jak2 
expression truly predicts progression of 
DN in humans, as well as tissue-specific 
Jak2 overexpression studies in animal 
models of DN. 
The absence of enhanced Jak2 
expression in the db/db C57BLKS and 
STZ-diabetic DBA/2J mouse DN models 
is interesting since these models, 
frequently used for studies of DN (10; 22; 
26; 27), develop high levels of 
albuminuria and undergo extensive early 
glomerular changes of DN (22; 26; 27), 
but rarely progress to severe 
glomerulosclerosis and do not develop 
significant tubulointerstitial fibrosis and 
progressive kidney failure (10; 26; 27).  
No increases in Jak2 mRNA or protein 
expression were found in either 
glomerular or tubulointerstitial 
compartments suggesting one possible 
reason for the lack of progressive DN 
induction in these mouse models.  It is 
certainly likely that additional responses 
critical for progression of human DN are 
missing in conventional murine models of 
DN and that protective responses in 
mouse models may be absent from 
humans with progressive DN.  Thus, the 
strategy of uncovering divergent 
responses between human progressive 
DN and murine models of early DN may 
reveal other pathways that are essential 
for the pathogenesis of DN and that are 
potential targets for therapeutic or 
prevention strategies.  
Since Jak/Stat pathways are activated 
by growth factors, cytokines or other 
upstream signals, and because Jak2 
protein activation is via 
autophosphorylation, enhanced Jak2 
expression should result in Stat tyrosine 
phosphorylation and activation only with 
Jak2 activation.  Thus, it was important to 
test whether Jak2 overexpression alone 
could induce Stat phosphorylation and 
other downstream responses.  While in 
vivo confirmation of such a response 
necessarily awaits the generation and 
testing of tissue specific Jak2 transgenic 
mice, we have confirmed that Jak2 
overexpression alone, without additional 
growth factors or cytokines, substantially 
increases Stat3 phosphorylation on 
tyrosine 705.  This observation confirms 
activation of Jak2/Stat3 signaling simply 
by overexpressing Jak2 in mouse 
mesangial cells.  Interestingly, high 
glucose alone had only a modest and 
statistically insignificant effect on Stat3 
phosphorylation implying that high 
glucose alone is not sufficient to trigger 
Jak2 signaling in our system.  However, 
high glucose had an additive effect on 
Jak2 overexpression on Stat3 
phosphorylation.  The molecular 
mechanism by which Jak2 
overexpression induces Stat3 
phosphorylation remains to be 
determined. 
Enhanced production of ROS has 
been described as a potential major 
activator of Jak/Stat signaling (33) and 
can occur independently of the addition of 
exogenous cytokines (34).  This 
phenomenon appears to be relatively 
general since ROS mediate induction of 
Jak2 activation in tissues such as cardiac 
myocytes and vascular smooth muscle 
cells (34-36) as well as kidney cells (12; 
14; 15; 32).  We did not test whether ROS 
could further augment the signaling to 
Stat3 in our Jak2 overexpressing cells but 
we did show that Jak2 overexpression 
induced ROS production in mesangial 
cells, especially those cultured in high 
glucose medium.  This observation 
suggests the presence of an amplification 
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loop in diabetic glomerular and proximal 
tubular cells in which there is both 
enhanced Jak2 expression, as shown in 
this study, as well as enhanced ROS 
production, due to metabolic alterations 
resulting from enhanced glucose flux (26; 
37).  These 2 independent processes can 
each enhance the other, leading to 
progressive downstream signaling from 
both pathways and inexorable fibrosis 
and kidney failure. 
Enhanced Jak2 expression in both 
glomerular and proximal tubule cells may 
stimulate a host of downstream 
processes that lead to the 
glomerulosclerosis, tubulointerstitial 
fibrosis and kidney failure that affects up 
to 40% of diabetic patients.  The absence 
of this response may protect mice from 
these late, but deadly, aspects of 
progressive DN.  Further exploration of 
Jak/Stat pathways in DN as well as 
additional systems analysis of the 
differences between mice and humans 
may elucidate targets for therapies that 
could help humans with DN be more like 
mice. 
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Figure 1. Jak/Stat canonical pathway in human DN as assessed by Ingenuity 
Pathway Analysis (IPA) software. The Jak/Stat family members represented include 
Jak1, Jak2, Jak3, Stat1, Stat2, Stat3, Stat4, Stat5A, Stat5B and Stat6. The mRNA 
expression changes for Jak/Stat family members in early (PIMA Indians, n=22-24) (left 
panel) and progressive (European, n=7-11) (right panel) human DN (DN) are indicated 
in red for increased expression and green for decreased expression, compared to the 
corresponding control group (LD+MCD, n=7-12). 2000-2008 Ingenuity Systems, Inc. All 
rights reserved. 
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Figure 2. Jak2 mRNA expression levels in human DN: correlation with renal 
function.  A. Increased expression of Jak2 mRNA in the glomeruli of early DN patients 
and in the tubulointerstitium of progressive DN patients compared to controls (n = 6-9 in 
the control group, n = 11-12 in the early DN group, n = 10-12 in the progressive DN 
group).  B. Correlation of tubulointerstitial Jak2 mRNA expression (as measured by real-
time RT-PCR) with eGFR in patients with early (black cross, n=11) and progressive (black 
circles, n=12) DN.  C. Representative Jak2 immunohistographs of kidney biopsies from 
patients with no kidney disease (Control), progressive DN (Prog. DN), hypertensive 
nephropathy (HTN), IgA nephropathy (IgAN) or lupus nephritis (LN).  Jak2 expression 
was substantially and significantly increased in the proximal tubular cells and glomeruli of 
the patients with DN compared to the control and not in other progressive kidney 
diseases. 
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Figure 3. Jak2 in the C57BLKS type2-DN and STZ-DBA/2J type1-DN mouse models. 
A. Jak2 real-time RT-PCR mRNA expression in cortex (n=6 control, n=7 diabetic) and 
glomeruli (n=5 control, n=7 diabetic) was not altered in db/db mice compared to db/m 
control animals.  B. Jak2 immunoblot (upper panel) and densitometry (lower panel).  
Jak2 protein levels were unchanged in the cortex (n=3 control, n=5 diabetic) and 
glomeruli (n=4 in both groups) of db/db mice vs. db/m mice.  C. Jak2 qRT-PCR mRNA 
expression in cortex and glomeruli was not altered in DBA/2J diabetic mice compared to 
control animals (n=5 in each group).  D. Jak2 immunoblot (upper panel) and 
densitometry (lower panel) in DBA/2J mice. Jak2 protein levels were not significantly 
different in the cortex or glomeruli of DBA/2J diabetic mice.  n.s. = statistically non-
significant. 
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Figure 4. Effects of Jak2 overexpression and high glucose on Stat3 
phosphorylation in Jak2 mesangial cells. 
Left panel: Jak2 (130 kDa), total Stat3 (79 kDa), phosphorylated Stat3 (79kDa) and β-
tubulin (50 kDa) immunoblots of murine mesangial cells transfected with a Jak2 prk-5 
plasmid or a control vector (n=3 per group). Right panel:  Phosphorylated Stat3 levels 
normalized to total Stat3 levels. 
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Figure 5. Effects of Jak2 overexpression and high glucose on ROS generation in 
mesangial cells. 
 Left panel:  DCF fluorescence in murine mesangial cells transfected with either Jak2 
prk-5 or control vectors exposed to 5.5 mM D-glucose + 24.5 mM mannitol, or 30 mM D-
glucose for 24h.  Image exposure times were identical and are representative of those 
from 3 separate fields on 5 separate slides for each condition. Right panel:  ROS 
quantitation from the DCF fluorescence experiments.  Fluorescence intensity was 
determined using NIH image J. (n=5 per group; 50 cells were assessed for each slide).  
 
 
 
